HC Wainwright Predicts Kamada’s Q1 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at HC Wainwright lifted their Q1 2026 EPS estimates for shares of Kamada in a report released on Thursday, March 12th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $0.14 per share for the quarter, up from their previous forecast of $0.10. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.16 EPS and FY2030 earnings at $0.88 EPS.

Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, March 11th. The biotechnology company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Kamada had a return on equity of 7.72% and a net margin of 11.19%.The business had revenue of $44.68 million during the quarter, compared to the consensus estimate of $145.07 million.

Several other brokerages also recently commented on KMDA. Stifel Nicolaus set a $11.00 target price on Kamada in a report on Wednesday. Benchmark restated a “buy” rating on shares of Kamada in a report on Thursday. Wall Street Zen lowered shares of Kamada from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Kamada Stock Up 0.1%

KMDA opened at $8.70 on Monday. The firm has a market cap of $500.34 million, a PE ratio of 24.86, a P/E/G ratio of 0.76 and a beta of 0.94. The business has a fifty day simple moving average of $8.44 and a 200-day simple moving average of $7.46. Kamada has a fifty-two week low of $5.54 and a fifty-two week high of $9.35.

Hedge Funds Weigh In On Kamada

Hedge funds have recently added to or reduced their stakes in the company. Barclays PLC raised its position in Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 3,862 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Kamada during the fourth quarter worth $66,000. Simplicity Wealth LLC acquired a new position in Kamada during the third quarter worth $70,000. XTX Topco Ltd bought a new position in Kamada during the fourth quarter valued at about $103,000. Finally, SIH Partners LLLP acquired a new stake in shares of Kamada in the fourth quarter worth about $134,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Dividend Announcement

The company also recently declared an annual dividend, which will be paid on Monday, April 6th. Stockholders of record on Monday, March 23rd will be issued a dividend of $0.25 per share. This represents a dividend yield of 292.0%. The ex-dividend date is Monday, March 23rd.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.